Find out more about Jake Shortt's experience
Jake Shortt's highlights
FEATURED Journal article
High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma
Read moreJake Shortt's selected work
AWAKENING DORMANT GENES TO HELP THE IMMUNE SYSTEM FIGHT BLOOD CANCERS
Research Grant
Distinct modulation of IFN gamma-induced transcription by BET bromodomain and catalytic P3..
Journal article
EXPLOITING AND DEFINING THE IMMUNE REGULATORY ACTIVITIES OF BET BROMODOMAIN INHIBITORS
Research Grant
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-..
Journal article
DISCOVERY OF NEW TREATMENTS FOR THERAPY-RESISTANT MULTIPLE MYELOMA.
Research Grant
Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
Journal article
Jake Shortt's selected work
Projects
Displaying the 5 most recent projects from 5 for Jake Shortt.
Project Types
5
Research Grant
Scholarly Works
Displaying the 10 most recent scholarly works from 120 for Jake Shortt.
Honours, Awards and Fellowships
Presidential Award
Albert Baikie Memorial Medal
FRCPA - Fellow of the Royal College of Pathologists of Australasia
FRACP - Fellow of the Royal Australasian College of Physicians
Credentials
Positions
Honorary
The Sir Peter Maccallum Department of Oncology
Education
Doctor of Philosophy
University of Melbourne
Bachelor of Medical Science with Distinction
University of Otago
Bachelor of Medicine and Bachelor of Surgery with Distinction
University of Otago